Skip to content

Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study

Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03879395
Acronym
SurgMelMet
Enrollment
15
Registered
2019-03-18
Start date
2010-01-01
Completion date
2018-12-31
Last updated
2024-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Tumor, Melanoma Metastatic, Melanoma Stage Iv

Keywords

melanoma, abdominal metastasis, metastasectomy, tumor resection, M1c

Brief summary

The aim is to conduct a single centre retrospective study of all patients with stage IV melanoma that underwent surgery for metastases at Sahlgrenska University Hospital between 2010-01-01 and 2018-12-31. Pre- and postoperative data will be collected from digital medical records, the Swedish Cancer Registry, the Swedish Cause of Death Register as well as from the national Swedish cancer patient database (INCA). If needed, patient records will be collected from other hospitals. Results will be presented in written format as a summary and analysis of the characteristics of the cases operated on during the inclusion period. The aim is to identify predictive and prognostic factors for outcome and complications in the surgical treatment of stage IV metastatic melanoma.

Interventions

PROCEDUREAbdominal surgery with metastasectomy

Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma

Sponsors

Vastra Gotaland Region
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Biopsy verified stage IV malignant melanoma, stage M1c. * Having undergone surgery with metastasectomy of melanoma tumors.

Exclusion criteria

* retroperitoneal tumors

Design outcomes

Primary

MeasureTime frameDescription
Overall survivalDecember 2018Overall survival

Secondary

MeasureTime frameDescription
Complications according to Clavien-Dindo within 90 days.90 daysComplications according to Clavien-Dindo within 90 days.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026